ARWR — Arrowhead Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $8.26bn
- $7.92bn
- $829.45m
Arrowhead Pharmaceuticals rises on promising early-stage data for obesity treatments
Brief: Arrowhead Pharmaceuticals Announces Interim Clinical Data On Rnai-Based Obesity Candidates
Brief: Arrowhead Pharmaceuticals Announces Health Canada Approval Of Redemplo™
U.S. RESEARCH ROUNDUP-APi Group, Elf Beauty, Tesla
Brief: Arrowhead Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Arrowhead rises as U.S. FDA grants breakthrough tag for rare blood fat disorder drug
Brief: Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation For Plozasiran
Nasdaq biotech index on track for record closing high
U.S. RESEARCH ROUNDUP- Amgen, Crowdstrike, Micron Technology
Arrowhead Pharma rises after genetic disorder drug gets US FDA nod
US FDA approves Arrowhead's genetic disorder drug (updated)
US FDA approves Arrowhead's genetic disorder drug
Brief: Arrowhead Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis
U.S. RESEARCH ROUNDUP- AGCO, Caterpillar, United Rentals
Brief: Arrowhead Pharmaceuticals Files CTA For Investigational Aro-Dimer-PA
Ionis, Arrowhead file dueling patent lawsuits over genetic-disorder drug
Brief: Arrowhead Pharmaceuticals Files Complaint For Declaratory Judgment Against Ionis Pharmaceuticals
Brief: Arrowhead Seeks Approval to Begin ARO-MAPT Alzheimer’s Trial